Literature DB >> 2988154

Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction.

J A Kauffman, J F Way, L S Siegel, L C Sellin.   

Abstract

Blockade of neuromuscular transmission was produced in the lower hind limb of the rat by local injection of either type A or type F botulinum toxin (BoTx). At 1, 3, 7, and 10 days after injection, the extensor digitorum longus (edl) nerve-muscle preparation was excised and analyzed for alterations in muscle mechanical properties or spontaneous and nerve stimulus-evoked quantal transmitter release. Muscles receiving type A toxin were paralyzed up to and including 7 days after injection. Muscles treated with type F toxin, although completely paralyzed at 1 and 3 days after injection, twitched in response to nerve stimulation by 7 days. Both toxins induced a marked decrease in the frequency of miniature end-plate potentials, but type A did so to a greater extent. Between 1 and 3 days after toxin injection nerve impulse-evoked transmitter release was reduced in both type A- and type F-treated muscles. Evoked release was temperature sensitive in type A-treated muscles but not in those treated with type F. 3,4-Diaminopyridine (3,4-DAP), a compound which increases nerve-evoked transmitter release by increasing Ca2+ influx, was more effective in reversing the paralysis in type A than in type F-treated muscles. 3,4-DAP induced asynchronous end-plate potentials in response to nerve stimulation in type F-paralyzed muscles, but not in muscles treated with type A. Amidination of the amino groups (presumably lysine) on the toxin by treatment with ethylacetimidate increased the potency and efficacy of only type F BoTx. The results show that type F BoTx differs from type A, mainly by its lower potency, efficacy, shorter duration of action, and by being less effectively antagonized by 3,4-DAP.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2988154     DOI: 10.1016/0041-008x(85)90342-4

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  14 in total

Review 1.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Authors:  E J Schantz; E A Johnson
Journal:  Microbiol Rev       Date:  1992-03

2.  Zinc antagonizes the effect of botulinum type A toxin at the mouse neuromuscular junction.

Authors:  M Nishimura; S Kozaki; G Sakaguchi
Journal:  Experientia       Date:  1988-01-15

3.  A study of synchronization of quantal transmitter release from mammalian motor endings by the use of botulinal toxins type A and D.

Authors:  J Molgó; L S Siegel; N Tabti; S Thesleff
Journal:  J Physiol       Date:  1989-04       Impact factor: 5.182

4.  Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A.

Authors:  M K Houser; G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

5.  Novel Native and Engineered Botulinum Neurotoxins.

Authors:  Lance Steward; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Handb Exp Pharmacol       Date:  2021

6.  Persistence of Botulinum neurotoxin inactivation of nerve function.

Authors:  Charles B Shoemaker; George A Oyler
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 7.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

8.  Botulinum toxin.

Authors:  P K Nigam; Anjana Nigam
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

9.  Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.

Authors:  G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

10.  Distinct sites of action of clostridial neurotoxins revealed by double-poisoning of mouse motor nerve terminals.

Authors:  M Gansel; R Penner; F Dreyer
Journal:  Pflugers Arch       Date:  1987-08       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.